MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Book Value 2011-2026 | OPK
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.37 B | 1.39 B | 1.56 B | 1.69 B | 1.67 B | 1.61 B | 1.79 B | 1.89 B | 2.09 B | 1.98 B | 836 M | 873 M | 203 M | 161 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 B | 161 M | 1.36 B |
Quarterly Book Value OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.3 B | 1.31 B | 1.4 B | 1.4 B | 1.25 B | 1.44 B | 1.54 B | 1.55 B | 1.56 B | 1.63 B | - | 1.61 B | 1.69 B | 1.77 B | 1.74 B | 1.7 B | 1.67 B | 1.67 B | 1.67 B | 1.67 B | 1.61 B | 1.61 B | 1.61 B | 1.61 B | 1.79 B | 1.79 B | 1.79 B | 1.79 B | 1.84 B | 1.86 B | 1.86 B | 1.86 B | 2.05 B | 2.09 B | 2.09 B | 2.09 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 836 M | 836 M | 836 M | 836 M | 873 M | 873 M | 873 M | 873 M | 203 M | 203 M | 203 M | 203 M | 185 M | 185 M | 185 M | 185 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 B | 185 M | 1.37 B |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
4.1 M | $ 2.13 | -2.74 % | $ 4.89 M |  USA |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M |  Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
456 M | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 195.6 | 0.17 % | $ 21.7 B | USA |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
2.75 B | $ 65.94 | -1.51 % | $ 25.7 B | USA |
 |
Co-Diagnostics
CODX
|
86 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | $ 104.91 | - | $ 19.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 16.33 | 5.29 % | $ 494 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
3.21 B | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
6.63 B | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
44.4 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Interpace Biosciences
IDXG
|
-2.22 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
1.61 B | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Agilent Technologies
A
|
5.39 B | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
DarioHealth Corp.
DRIO
|
110 M | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
-99.3 M | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B |  Niderland |
 |
CareDx, Inc
CDNA
|
303 M | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Celcuity
CELC
|
116 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Medpace Holdings
MEDP
|
459 M | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 264.42 | 0.54 % | $ 22 B | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
368 M | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
2.56 M | $ 3.48 | 0.87 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
837 M | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
National Research Corporation
NRC
|
14 M | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
706 M | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.39 | 4.51 % | $ 417 M | USA |
 |
RadNet
RDNT
|
1.36 B | $ 61.74 | 0.41 % | $ 4.64 B | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |